Though highly effective, medications for the prevention of chronic kidney disease progression are under-utilized, emphasizing the need for better use of prognostic tools.

Among patients with type 2 diabetes, use of GLP-1 agonists may increase the risks for adhesive capsulitis and required ...

UK: A recent consensus statement from leading UK medical organizations-including the Association of Anaesthetists,the ...

Women prescribed a GLP-1 receptor agonist up to 2 years before conception were less likely to develop hypertensive disorders ...

After just a few years on the market, a new wave of GLP-1 drugs approved for weight loss have upended what we know about obesity. By now, these are household names: Mounjaro. Wegovy. Zepbound ...

Share on Pinterest Women with diabetes may get the strongest cardiovascular protection from GLP-1 agonists. Image credit: Kathryn Gamble for The Washington Post via Getty Images. Diabetes ...

They work by mimicking the action of a hormone called glucagon-like peptide 1 (hence GLP-1), stimulating the body to produce more insulin and decreasing blood sugar spikes by slowing digestion.

A final-stage study has found that exenatide, a GLP-1 drug used to treat Type 2 diabetes, showed no benefit in slowing the progression of Parkinson's disease. The 96-week trial, published in The ...

With one in eight Americans having taken a GLP-1 already — including 43% of those with diabetes and a quarter of people with heart disease — it’s time to shift our thinking on GLP-1s to ...

Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...

As glucagon-like peptide 1 (GLP-1) receptor agonist use becomes more prevalent, patients are using them for new indications — and at new dosages. Say hello to microdosing, or taking doses lower ...

Some of the most common peptides for weight loss belong to a class of drugs called glucagon-like peptide 1 (GLP-1) receptor agonists. These medications mimic the action of the natural hormone GLP ...